KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Gross Profit: 2009-2024

Historic Gross Profit for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $13.1 billion.

  • Regeneron Pharmaceuticals' Gross Profit rose 0.43% to $3.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 billion, marking a year-over-year increase of 2.11%. This contributed to the annual value of $13.1 billion for FY2024, which is 7.63% up from last year.
  • Regeneron Pharmaceuticals' Gross Profit amounted to $13.1 billion in FY2024, which was up 7.63% from $12.2 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Gross Profit registered a high of $14.3 billion during FY2021, and its lowest value of $7.9 billion during FY2020.
  • For the 3-year period, Regeneron Pharmaceuticals' Gross Profit averaged around $12.2 billion, with its median value being $12.2 billion (2023).
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Gross Profit spiked by 81.71% in 2021, and later declined by 20.46% in 2022.
  • Regeneron Pharmaceuticals' Gross Profit (Yearly) stood at $7.9 billion in 2020, then soared by 81.71% to $14.3 billion in 2021, then declined by 20.46% to $11.4 billion in 2022, then climbed by 7.14% to $12.2 billion in 2023, then increased by 7.63% to $13.1 billion in 2024.